JP6204930B2 - 多価ワクチンによる黄色ブドウ球菌感染症からの保護 - Google Patents

多価ワクチンによる黄色ブドウ球菌感染症からの保護 Download PDF

Info

Publication number
JP6204930B2
JP6204930B2 JP2014561022A JP2014561022A JP6204930B2 JP 6204930 B2 JP6204930 B2 JP 6204930B2 JP 2014561022 A JP2014561022 A JP 2014561022A JP 2014561022 A JP2014561022 A JP 2014561022A JP 6204930 B2 JP6204930 B2 JP 6204930B2
Authority
JP
Japan
Prior art keywords
aureus
infection
vaccine
staphylococcus aureus
vaccine formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014561022A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015510883A5 (enExample
JP2015510883A (ja
Inventor
マーク シャートリフ
マーク シャートリフ
ジャネット ハロ
ジャネット ハロ
ジェフリー リード
ジェフリー リード
Original Assignee
ユニバーシティ オブ メリーランド，ボルチモア
ユニバーシティ オブ メリーランド，ボルチモア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティ オブ メリーランド，ボルチモア, ユニバーシティ オブ メリーランド，ボルチモア filed Critical ユニバーシティ オブ メリーランド，ボルチモア
Publication of JP2015510883A publication Critical patent/JP2015510883A/ja
Publication of JP2015510883A5 publication Critical patent/JP2015510883A5/ja
Application granted granted Critical
Publication of JP6204930B2 publication Critical patent/JP6204930B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2014561022A 2012-03-05 2013-03-05 多価ワクチンによる黄色ブドウ球菌感染症からの保護 Expired - Fee Related JP6204930B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261606750P 2012-03-05 2012-03-05
US61/606,750 2012-03-05
PCT/US2013/029053 WO2013134225A1 (en) 2012-03-05 2013-03-05 Multivalent vaccine protection from staphylococcus aureus infection

Publications (3)

Publication Number Publication Date
JP2015510883A JP2015510883A (ja) 2015-04-13
JP2015510883A5 JP2015510883A5 (enExample) 2016-04-21
JP6204930B2 true JP6204930B2 (ja) 2017-09-27

Family

ID=49117246

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014561022A Expired - Fee Related JP6204930B2 (ja) 2012-03-05 2013-03-05 多価ワクチンによる黄色ブドウ球菌感染症からの保護

Country Status (6)

Country Link
US (2) USRE48137E1 (enExample)
EP (1) EP2822582B1 (enExample)
JP (1) JP6204930B2 (enExample)
CA (1) CA2865620A1 (enExample)
ES (1) ES2642892T3 (enExample)
WO (1) WO2013134225A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0811530B1 (pt) 2007-05-14 2019-01-02 Research Foundation Of State Univ Of New York composição compreendendo indutor(es) de resposta fisiológica à dispersão ácido decanóico, superfície, solução, método ex vivo de tratamento ou inibição da formação de um biofilme sobre uma superfície
WO2015171693A1 (en) * 2014-05-06 2015-11-12 Virginia Commonwealth University A new target for firmicutes and related bacteria: the prp protease
CA3042015A1 (en) 2016-10-26 2018-05-03 Modernatx, Inc. Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
EP3600358A1 (en) * 2017-03-31 2020-02-05 Acell, Inc. Extracellular matrix compositions with bactericidal or bacteriostatic characteristics useful for protecting and treating patients with bacterial infections
MX2020005875A (es) 2017-12-05 2020-10-08 Bioplx Inc Métodos y composiciones para prevenir la infección microbiana.
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
CA3204730A1 (en) * 2021-01-15 2022-07-21 Gowrishankar MUTHUKRISHNAN Staphylococcus aureus antigen-based nucleic acid vaccines
CN112940987B (zh) * 2021-04-10 2022-10-14 福建省农业科学院畜牧兽医研究所 一株兔金黄色葡萄球菌及其在制备灭活疫苗中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
WO2004018624A2 (en) 2002-08-20 2004-03-04 Chiron Corporation Random transposon insertion in staphylococcus aureus and use thereof to identify essential genes
NZ570805A (en) 2006-03-30 2011-10-28 Glaxosmithkline Biolog Sa Vaccine comprising Type 5 and Type 8 capsular polysaccharides from Staphyloccocus aureus
EP2176662B1 (en) 2007-07-30 2012-03-28 The Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And Behalf Of Methods and devices for the detection of biofilm
US8318180B2 (en) 2008-09-30 2012-11-27 University Of Maryland, Baltimore Protective vaccine against Staphylococcus aureus biofilms comprising cell wall-associated immunogens

Also Published As

Publication number Publication date
ES2642892T3 (es) 2017-11-20
CA2865620A1 (en) 2013-09-12
EP2822582A4 (en) 2015-12-30
WO2013134225A1 (en) 2013-09-12
US9265820B2 (en) 2016-02-23
EP2822582A1 (en) 2015-01-14
USRE48137E1 (en) 2020-08-04
EP2822582B1 (en) 2017-09-13
US20150024000A1 (en) 2015-01-22
JP2015510883A (ja) 2015-04-13

Similar Documents

Publication Publication Date Title
JP2015510883A (ja) 多価ワクチンによる黄色ブドウ球菌感染症からの保護
Kurlenda et al. Alternative therapies in Staphylococcus aureus diseases
Gomes et al. Control of bovine mastitis: old and recent therapeutic approaches
Lee et al. Klebsiella pneumoniae secretes outer membrane vesicles that induce the innate immune response
CN102657855B (zh) 用于进行抗葡萄球菌接种的免疫原性组合物
US8318180B2 (en) Protective vaccine against Staphylococcus aureus biofilms comprising cell wall-associated immunogens
JP6495821B2 (ja) ペプチドおよびそれらの使用
US20140314823A1 (en) Antimicrobial peptides
JP2015510883A5 (enExample)
WO2013032964A1 (en) Compositions and methods for preventing and treating biofilms
CN108883134A (zh) 活化干细胞和用于感染伤口的全身治疗方法
EP2799068A1 (en) Antimicrobial compositions and methods for their production
JP2022084752A (ja) 環状抗微生物性擬ペプチド及びその使用
CN110124012B (zh) 一种颗粒溶素作为多粘菌素类抗生素增效剂的应用
ES2366735A1 (es) Vacuna frente a acinetobacter baumannii.
US8691242B2 (en) Staphylococcus aureus DIV1B for use as vaccine
JP2004175733A (ja) 薬剤耐性菌による感染症治療剤
TWI394578B (zh) 抗菌蛋白之新用途
WO2016146037A1 (zh) 用于抑制/瓦解生物被膜的抑制剂及其应用
CN111569079B (zh) 一种抗葡萄球菌感染的抗体抗生素联合制剂
RU2813626C1 (ru) Модифицированный эндолизин и антибактериальные композиции на его основе для лечения инфекций, вызванных бактериями Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli
CN103458681A (zh) 用于预防感染、降低感染的严重性、及治疗感染的胸腺素α肽
US20140120191A1 (en) Method of treating a disorder associated with sequestered bacteria
US20220160857A1 (en) Multivalent vaccines derived from klebsiella out membrane proteins
WO2022261360A1 (en) Plyss2 lysins and variants thereof for use against multidrug resistant gram-positive bacteria

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160301

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170608

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170808

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170901

R150 Certificate of patent or registration of utility model

Ref document number: 6204930

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees